Compare Sony Group Corp (SONY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Zoetis Inc — how do they compare? Sony Group Corp trades at $24.18 (market cap $136.87B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Sony Group Corp is far larger — about 4.5× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and Zoetis Inc for 70 Days on average.
| SONY | ZTS | |
|---|---|---|
Market Cap | $136.87B | $30.20B |
Volume | 5,364,503 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $30.26 | $147.53 |
52-Week Low | $19.32 | $69.09 |
Typical Hold Time | 96 Days | 70 Days |
Enterprise Value | $134.77B | $37.76B |
Dividend Yield | 0.66% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony (SONY) trades at $24.24, up 3.06% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with improved net income of $1.14T in 2025, though 2026 projections show a net loss. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content strength and legal actions against AI copyright infringement.
Sony presents a mixed outlook with strong entertainment assets and improving cash flow offset by projected 2026 profitability challenges. The stock's current valuation metrics appear reasonable, but investors should monitor execution risks in content monetization and competitive pressures in the entertainment sector. The bullish analyst sentiment and technical momentum suggest near-term upside potential.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
